LIRAGLUTIDE LUPIN (Taevas Life Sciences Pty Ltd)
Product name
LIRAGLUTIDE LUPIN
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
174 (255 working days)
Active ingredients
Liraglutide
Registration type
NCE/NBE
Indication
[TRADE NAME] is indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management in adult patients with an initial Body Mass Index (BMI) of
- ≥30 kg/m2 (obese) or
- ≥27 kg/m2 to <30 kg/m2 (overweight) in the presence of at least one weight related comorbidity, such as dysglycaemia (pre-diabetes and type 2 diabetes mellitus), hypertension, dyslipidaemia, or obstructive sleep apnoea.